The Story of Maryland’s Cell and Gene Therapy Cluster is Shared Loud and Clear at Inaugural Bio Innovation Conference October 8, 2019 On Monday morning in Bethesda, Maryland hundreds of industry leaders emerged from a large ballroom at the inaugural Bio Innovation Conference, hosted by Maryland Life Sciences, a division of the Maryland Tech Council. [….]
Presented by Maryland Life Sciences (MDLS), a division of the Maryland Tech Council, the Bio Innovation Conference showcases Maryland’s innovation and success in the life sciences industry. The Bio Innovation Conference will connect more than 300 top life sciences professionals in the region with leading global brands, venture capitalists and promising startups, while embracing the [….]
Bio Innovation Conference to Highlight Cell and Gene Therapy Industry & Why Maryland is Becoming the #1 Destination for Biotech Companies October 3, 2019 The cell and gene therapy field has exploded over the past few years. Fueled by innovations in immunotherapy, cell engineering and biomanufacturing, as well as landmark FDA approvals, a new era [….]
BHCR Retains #4 Ranking in GEN’s Top 10 U.S. Biopharma Clusters – Here’s Why. “Top 3 By 2023” has been the slogan for the Biohealth Capital Region (BHCR) over the past few years adopted by many economic development and industry leaders across Maryland, DC, and Virginia. After more than four years of organized effort across [….]
Reprogramming the Human Computer: Silicon Valley Meets Cell and Gene Therapy How will Cell and Gene Therapy Usher in a New Industrial Revolution? Cell and gene therapy companies are on the verge of transforming how we treat unmet medical needs such as cancer, rare diseases, genetic disorders and diabetes, to name only a few. By [….]
Paragon Gene Therapy
Five Cell and Gene Therapy Companies that Are Changing the Landscape of the Field
#BIO2019 BIO Convention in Philadelphia
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, 2019 – Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody [….]
Paragon BioServices gets $1.2B Acquisition Deal by Catalent after launch of New Gene Therapy Manufacturing Facility April 15, 2019 Paragon BioServices, the home-grown Maryland biotech company that started in a Baltimore incubator 30 years ago, has grown to more than 400 employees and is two weeks away from beginning production in a brand new 150,000 [….]
